TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01316016

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rose hip
Description: 40 g of rose hip powder daily for 6 weeks.
Study: NCT03880539

Intervention type: DRUG
Group type: OTHER
Intervention: bezlotoxumab
Description: Adding BEZLO to SOC oral VAN pulse/taper

Intervention type: DRUG
Group type: OTHER
Intervention: Vancomycin Oral
Description: SOC vancomycin pulse/taper
Study: NCT01439789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhNRG-1
Description: day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
Study: NCT02842827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bomedemstat
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tretinoin
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tretinoin
Description: oral administration
Study: NCT01439789

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: day1\~day10:0.6ug/kg/day,10hours per day for vein infusion
Study: NCT03741153

Intervention type: DEVICE
Intervention: slit lamp
Description: 1. Presence of white grayish exfoliation material on the anterior lens capsule and / or the pupillary margin.~2. Poor pupillary dilatation due to atrophy of the dilator pupillae muscle.~3. The presence of pseudoexfoliative material (PXF)in cilliary processes and zonules.~4. presence of PXF material scattered on corneal endothelium.~5. Flecks of the exfoliative material on the anterior chamber which leads to glaucoma.

Intervention type: DEVICE
Intervention: slit lamp
Description: 1. Presence of white grayish exfoliation material on the anterior lens capsule and / or the pupillary margin.~2. Poor pupillary dilatation due to atrophy of the dilator pupillae muscle.~3. The presence of pseudoexfoliative material (PXF)in cilliary processes and zonules.~4. presence of PXF material scattered on corneal endothelium.~5. Flecks of the exfoliative material on the anterior chamber which leads to glaucoma.
Study: NCT05051748

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opalescence™ boost™ PF 40%
Description: 40% hydrogen peroxide in-office bleaching

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opalescence™ boost™ PF 40%
Description: 40% hydrogen peroxide in-office bleaching

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opalescence™ boost™ PF 40%
Description: 40% hydrogen peroxide in-office bleaching

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opalescence™ boost™ PF 40%
Description: 40% hydrogen peroxide in-office bleaching

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opalustre™
Description: 6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opalustre™
Description: 6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opalustre™
Description: 6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opalustre™
Description: 6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MI-Paste Plus®
Description: casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MI-Paste Plus®
Description: casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MI-Paste Plus®
Description: casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MI-Paste Plus®
Description: casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème
Study: NCT04537975

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C2Rx
Description: Hemofiltration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Standard of care that excludes any protocol restrictions.
Study: NCT03372785

Intervention type: DRUG
Intervention: aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor
Description: Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.

Intervention type: DRUG
Intervention: aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor
Description: Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.

Intervention type: DEVICE
Intervention: coronary wires. stents or coronary balloons
Description: all species of drug-eluting stent ((such as Xience, Endeavor, Resolute) implantation or balloon expansion (POBA)

Intervention type: DEVICE
Intervention: coronary wires. stents or coronary balloons
Description: all species of drug-eluting stent ((such as Xience, Endeavor, Resolute) implantation or balloon expansion (POBA)
Study: NCT04541407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide plus Osimertinib
Description: Temozolomide is an oral alkylating chemotherapy which has good CNS penetration and has demonstrated CNS responses in both primary brain tumors (e.g., glioblastoma and anaplastic astrocytoma) and in small cell lung cancer (SCLC) brain metastases. Preclinical data from glioblastoma suggests potential synergy of concurrent ALK or EGFR inhibition with temozolomide and early phase trials in glioblastoma are ongoing investigating such combinations. It is felt that combining temozolomide with osimertinib or lorlatinib may be beneficial for patients with progressive CNS disease on either of these TKIs because of the high CNS penetration of temozolomide, good CNS activity of temozolomide in other tumor types and preclinical data from glioblastoma suggesting a potential enhanced effect of concurrent EGFR and ALK/ROS1 inhibition with temozolomide.
Study: NCT02842827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tretinoin
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tretinoin
Description: oral administration
Study: NCT03915704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shotblocker
Description: Injection was administered with ShotBlocker.The Shotblocker application to all children in this group was done by the second researcher. After the injection, the shotblocker was wiped with 70% alcohol.
Study: NCT04541407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide plus Lorlatinib
Description: Temozolomide is an oral alkylating chemotherapy which has good CNS penetration and has demonstrated CNS responses in both primary brain tumors (e.g., glioblastoma and anaplastic astrocytoma) and in small cell lung cancer (SCLC) brain metastases. Preclinical data from glioblastoma suggests potential synergy of concurrent ALK or EGFR inhibition with temozolomide and early phase trials in glioblastoma are ongoing investigating such combinations. It is felt that combining temozolomide with osimertinib or lorlatinib may be beneficial for patients with progressive CNS disease on either of these TKIs because of the high CNS penetration of temozolomide, good CNS activity of temozolomide in other tumor types and preclinical data from glioblastoma suggesting a potential enhanced effect of concurrent EGFR and ALK/ROS1 inhibition with temozolomide
Study: NCT03684863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: observation
Study: NCT02918617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control toothpaste containing Novamin® technology

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control toothpaste containing 1500 ppm fluoride as MFP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test toothpaste with nano-HAP (high concentration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test toothpaste with nano-HAP (low concentration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test toothpaste with nano-HAP and (Potassium Nitrate) KNO3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control toothpaste without nano-HAP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test toothpaste with nano-HAP (medium concentration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test cream with nano-HAP (higher concentration)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control cream without nano-HAP
Study: NCT03577275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NST-4016 600mg
Description: Likely maximum therapeutic dose of NST-4016

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo for comparison with moxifloxacin and potential NST-4016 effects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Description: Active comparator with known effect on QT interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NST-4016 2000mg
Description: Supratherapeutic dose of NST-4016
Study: NCT04464863

Intervention type: OTHER
Intervention: Kinematic metrics
Description: kinematic metrics recorded with Kinect (register brand) and extracted with Akira (register brand)

Intervention type: OTHER
Intervention: Kinematic metrics
Description: kinematic metrics recorded with Kinect (register brand) and extracted with Akira (register brand)
Study: NCT04034368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide (TAF)
Description: Tenofovir alafenamide (TAF) 25 mg QD, oral administration, 48 weeks；
Study: NCT02994108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: txt2protect
Description: Text messages sharing HIV/STI prevention information with a focus on HPV infection and vaccination.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sexual Health Control
Description: Text messages sharing HIV/STI prevention and healthy relationship building information, including information about HPV infection and vaccination.
Study: NCT02219464

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasopharyngeal catheter

Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal Cannula

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Oxygen Supplementation
Description: Initially set at 3 liters/minute

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen Supplementation
Description: Initially set at 3 liters/minute

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sedation
Description: Midazolam 2mg IV, Fentanyl 100mcg IV, Propofol 100 mcg/kg/min. Additional doses of propofol at the discretion of the attending anesthesiologist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedation
Description: Midazolam 2mg IV, Fentanyl 100mcg IV, Propofol 100 mcg/kg/min. Additional doses of propofol at the discretion of the attending anesthesiologist.
Study: NCT04834180

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric diet plan
Description: The hypocaloric diet is one in which there is a reduction of daily calories or foods with high caloric density usually in order to aid weight loss.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Hypocaloric diet plan
Description: The hypocaloric diet is one in which there is a reduction of daily calories or foods with high caloric density usually in order to aid weight loss.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auricular Acupuncture
Description: Auriculotherapy is a technique derived from traditional acupuncture developed into a distinct treatment system of its own. It is based on either, the introduction of needles (auricular acupuncture), or pressure with Vaccaria seeds (acupressure). Those forms of auriculotherapy are applied on a set of anatomical maps at a specific point in the auricular region.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupressure
Description: Auriculotherapy is a technique derived from traditional acupuncture developed into a distinct treatment system of its own. It is based on either, the introduction of needles (auricular acupuncture), or pressure with Vaccaria seeds (acupressure). Those forms of auriculotherapy are applied on a set of anatomical maps at a specific point in the auricular region.
Study: NCT04936906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extra Care (EC) Intervention
Description: The EC intervention includes pre- and post- procedure calls from the surgeon, written educational material, personalized music during the operation, post-procedure skin cancer protection education, and are allowed to bring a guest into the procedure room.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (UC)
Description: Standard of care pre and post surgery management provided to patients undergoing Mohs Surgery.
Study: NCT01102335

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter arterial chemoembolization (TACE)
Description: The procedure is performed under local anaesthesia. The femoral artery at groin region is punctured for arterial access. Angiography is performed for demonstration of vascular structures before embolization.The arteries supplying the tumor are selectively catheterized, this includes the hepatic arteries or other extrahepatic collateral arteries.The chemotherapeutic agent(s) is mixed with lipiodol (an oily contrast) to enhance tumour uptake. Following delivery of the lipiodol/chemotherapy mixture, small gelfoam particles may be injected to reinforce the effect of treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE)
Description: The procedure is performed under local anaesthesia. The femoral artery at groin region is punctured for arterial access. Angiography is performed for demonstration of vascular structures before embolization.The arteries supplying the tumor are selectively catheterized, this includes the hepatic arteries or other extrahepatic collateral arteries.The chemotherapeutic agent(s) is mixed with lipiodol (an oily contrast) to enhance tumour uptake. Following delivery of the lipiodol/chemotherapy mixture, small gelfoam particles may be injected to reinforce the effect of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: anti-HBV drug
Study: NCT03346434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Solution for injection, subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Solution for injection, subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Solution for injection, subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Solution for injection, subcutaneous (SC)
Study: NCT04781335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexycu
Description: This is a contra-lateral randomized study, meaning that in clinic after a patient is identified as a candidate we will flip a coin for selection of the eye that is going to receive the Dexycu™ implant (the implant will be placed intracapsularly at the optic haptic junction of the IOL). The patients will receive the SAME topical regimen (Eye with Dexycu™: no steroid, Eye without Dexycu™: steroid will be used). The Dexycu™, topical NSAID, and antibiotic regimen will be provided to all patients in the study, at no cost, in order to avoid difficulties with compliance, insurance, and follow up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care post operative eye drops (steroid, antibiotic, NSAID)
Description: This is a contra-lateral randomized study, meaning that in clinic after a patient is identified as a candidate we will flip a coin for selection of the eye that is going to receive the Dexycu™ implant (the implant will be placed intracapsularly at the optic haptic junction of the IOL). The patients will receive the SAME topical regimen (Eye with Dexycu™: no steroid, Eye without Dexycu™: steroid will be used). The Dexycu™, topical NSAID, and antibiotic regimen will be provided to all patients in the study, at no cost, in order to avoid difficulties with compliance, insurance, and follow up.
Study: NCT02602366

Intervention type: OTHER
Group type: OTHER
Intervention: HEC Placebo Gel

Intervention type: OTHER
Group type: OTHER
Intervention: HEC Placebo Gel

Intervention type: OTHER
Group type: OTHER
Intervention: HEC Placebo Gel

Intervention type: OTHER
Group type: OTHER
Intervention: HEC Placebo Gel

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Vaginal Insert

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Vaginal Insert

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Vaginal Insert

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Vaginal Insert

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Vaginal Film

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Vaginal Film

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Vaginal Film

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Vaginal Film

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Intravaginal ring (IVR)

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Intravaginal ring (IVR)

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Intravaginal ring (IVR)

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Intravaginal ring (IVR)
Study: NCT01447654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: 100 mg for 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg for 12 months.
Study: NCT01925885

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI Ablation
Description: PVI ablation for atrial fibrillation specifically targets areas in the left atrium in the area just outside the pulmonary veins to eliminate triggers of atrial fibrillation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FIRM Ablation
Description: Ablation for atrial fibrillation specifically targets areas in the left or right atrium to eliminate areas that maintain atrial fibrillation without isolating the pulmonary veins
Study: NCT01218334

Intervention type: DEVICE
Intervention: 12 Lead Glove
Description: Comparison of EKG's derived from the 12 Lead Glove vs. the Gold Standard EKG machine
Study: NCT02149914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ryodoraku
Description: Ryodoraku to assess the energy of meridian system for each patient before and after taking the medication

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANSWatch
Description: ANSWatch to assess the autonomic nervous system for each patient before and after taking the medication

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UGI endoscopy
Description: UGI endoscopy to assess the grade of reflux esophagitis for each patient before and after taking the medication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GerdQ
Description: GerdQ to assess the severity of GERD for each patient before and after taking the medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI
Study: NCT02857517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conbercept
Description: 0.05ml conbercept
Study: NCT03065816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z0063
Description: Pharmaceutical form: chewable tablets Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z0063
Description: Pharmaceutical form: chewable tablets Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gaviscon
Description: Pharmaceutical form: chewable tablets Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gaviscon
Description: Pharmaceutical form: chewable tablets Route of administration: oral
Study: NCT02356276

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: D2 lymphadenectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy
Description: The first HIPEC is conducted within 48 h after surgery: Normal saline 3000 -4000ml, Paclitaxel 75mg/m\^2, 43°C, 60min. The second HIPEC is performed after 24 hours of the first HIPEC. The regimens are Paclitaxel 100 mg/m\^2, 43°C, 60min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Systemic chemotherapy (XELOX or SOX regimens)
Description: XELOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; Capecitabine: 1 g/m\^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.~SOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; S-1, 40 mg/m\^2 bid, po, day 1-14 (S-1: BSA \<1.25m\^2, 40mg bid, 1.25m\^2≤ BSA ≤1.5m\^2, 50mg bid, BSA\>1.5m\^2, 60 mg bid) bid, d1-14, po, every 3 weeks for a total of 6-8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy (XELOX or SOX regimens)
Description: XELOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; Capecitabine: 1 g/m\^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.~SOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; S-1, 40 mg/m\^2 bid, po, day 1-14 (S-1: BSA \<1.25m\^2, 40mg bid, 1.25m\^2≤ BSA ≤1.5m\^2, 50mg bid, BSA\>1.5m\^2, 60 mg bid) bid, d1-14, po, every 3 weeks for a total of 6-8 cycles.